Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMACare: AAA617 Alone or With ARPI in PSMA-Positive Castration-Resistant Prostate Cancer
NCT05849298Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by Novartis. Primary endpoint: Prostate-Specific Antigen response up to 5 years. Started Jan 2024; status: active, not recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT05849298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849298.